HRP20110400T1 - Derivati 2-(1h-indolilsulfanil)-benzil amina kao ssri - Google Patents
Derivati 2-(1h-indolilsulfanil)-benzil amina kao ssri Download PDFInfo
- Publication number
- HRP20110400T1 HRP20110400T1 HR20110400T HRP20110400T HRP20110400T1 HR P20110400 T1 HRP20110400 T1 HR P20110400T1 HR 20110400 T HR20110400 T HR 20110400T HR P20110400 T HRP20110400 T HR P20110400T HR P20110400 T1 HRP20110400 T1 HR P20110400T1
- Authority
- HR
- Croatia
- Prior art keywords
- alk
- disorder
- compound according
- atom
- hydrogen
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 claims abstract 4
- -1 2-(1H-indolylsulfanyl)-benzyl Chemical group 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004434 sulfur atom Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 208000017194 Affective disease Diseases 0.000 claims 3
- 150000002475 indoles Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000007613 Shoulder Pain Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Spoj opće formule I: naznačen time što je atom sumpora pričvršćen za indol preko bilo kojeg atoma ugljika u indolovom prstenu i pri čemu R1-R2 su nezavisno izabrani između vodika, C1-6-alk(en/in)ila, C3-8-cikloalk(en)ila, i C3-8-cikloalk(en)il-C1-6-alk(en/in)ila ili R1 i R2 zajedno sa dušikom obrazuju 4-7-člani prsten koji sadrži nula ili jednu dvostruku vezu, dok spomenuti prsten pored spomenutog dušika eventualno sadrži još jedan heteroatom izabran između dušika, kisika i sumpora; R3-R12 su nezavisno izabrani između vodika, halogena, cijano, nitro, C1-6-alk(en/in)ila, C3-8-cikloalk(en)ila, C3-8-cikloalk(en)il-C1-6-alk(en/in)ila, amino, C1-6-alk(en/in)ilamino, di-(C1-6-alk(en/in)il)amino, C1-6-alk(en/in)ilkarbonila, aminokarbonila, C1-6-alk(en/in)ilaminokarbonila, di-(C1-6-alk(en/in)il)aminokarbonila, hidroksi, C1-6-alk(en/in)iloksi, C1-6-alk(en/in)iltio, halo-C1-6-alk(en/in)ila, halo-C1-6-alk(en/in)ilsulfonila, halo-C1-6-alk(en/in)ilsulfanila i C1-6-alk(en/in)ilsulfonila; iR13 je izabran između vodika i C1-6-alkila; uz uvjet da je R10 različit od halogena, cijano, C1-6alk(en/in)ila, hidroksila, C1-6alk(en/in)iloksi i halo- C1-6alk(en/in)ilau vidu njegove slobodne baze ili soli; uz uvjete da: kada je atom sumpora pričvršćen preko atoma br. 2 indola, onda R7 ne postoji; kada je atom sumpora pričvršćen preko atoma br. 3 indola, onda R12 ne postoji; kada je atom sumpora pričvršćen preko atoma br. 4 indola, onda R8 ne postoji; kada je atom sumpora pričvršćen preko atoma br. 5 indola, onda R9 ne postoji; kada je atom sumpora pričvršćen preko atoma br. 6 indola, onda R10 ne postoji; ikada je atom sumpora pričvršćen preko atoma br. 7 indola, onda R11 ne postoji. Patent sadrži još 15 patentnih zahtjeva.
Claims (16)
1. Spoj opće formule I:
[image]
naznačen time što je atom sumpora pričvršćen za indol preko bilo kojeg atoma ugljika u indolovom prstenu i pri čemu
R1-R2 su nezavisno izabrani između vodika, C1-6-alk(en/in)ila, C3-8-cikloalk(en)ila, i C3-8-cikloalk(en)il-C1-6-alk(en/in)ila ili R1 i R2 zajedno sa dušikom obrazuju 4-7-člani prsten koji sadrži nula ili jednu dvostruku vezu, dok spomenuti prsten pored spomenutog dušika eventualno sadrži još jedan heteroatom izabran između dušika, kisika i sumpora;
R3-R12 su nezavisno izabrani između vodika, halogena, cijano, nitro, C1-6-alk(en/in)ila, C3-8-cikloalk(en)ila, C3-8-cikloalk(en)il-C1-6-alk(en/in)ila, amino, C1-6-alk(en/in)ilamino, di-(C1-6-alk(en/in)il)amino, C1-6-alk(en/in)ilkarbonila, aminokarbonila, C1-6-alk(en/in)ilaminokarbonila, di-(C1-6-alk(en/in)il)aminokarbonila, hidroksi, C1-6-alk(en/in)iloksi, C1-6-alk(en/in)iltio, halo-C1-6-alk(en/in)ila, halo-C1-6-alk(en/in)ilsulfonila, halo-C1-6-alk(en/in)ilsulfanila i C1-6-alk(en/in)ilsulfonila; i
R13 je izabran između vodika i C1-6-alkila;
uz uvjet da je R10 različit od halogena, cijano, C1-6alk(en/in)ila, hidroksila,
C1-6alk(en/in)iloksi i halo- C1-6alk(en/in)ila
u vidu njegove slobodne baze ili soli;
uz uvjete da:
kada je atom sumpora pričvršćen preko atoma br. 2 indola, onda R7 ne postoji;
kada je atom sumpora pričvršćen preko atoma br. 3 indola, onda R12 ne postoji;
kada je atom sumpora pričvršćen preko atoma br. 4 indola, onda R8 ne postoji;
kada je atom sumpora pričvršćen preko atoma br. 5 indola, onda R9 ne postoji;
kada je atom sumpora pričvršćen preko atoma br. 6 indola, onda R10 ne postoji; i
kada je atom sumpora pričvršćen preko atoma br. 7 indola, onda R11 ne postoji.
2. Spoj prema zahtjevu 1, naznačen time, što su su R1 i R2 nezavisno izabrani između vodika i C1-6-alk(en/in)ila; ili R1 i R2 zajedno sa dušikom obrazuju 4-7-člani prsten koji sadrži nula ili jednu dvostruku vezu, dok prsten pored dušika eventualno sadrži još jedan heteroatom izabran između dušika, kisika i sumpora.
3. Spoj prema bilo kojem od zahtjeva 1 i 2, naznačen time, što su R3-R12 nezavisno izabrani između vodika, halogena, cijano, C1-6-alk(en/in)ila, hidroksi, C1-6-alk(en/in)iloksi i halo-C1-6-alk(en/in)ila.
4. Spoj prema bilo kojem od zahtjeva 1-3, naznačen time, što su R3-R6 nezavisno izabrani između vodika, halogena i C1-6-alk(en/in)ila.
5. Spoj prema bilo kojem od zahtjeva 1-4, naznačen time, što su R7-R12 nezavisno izabrani između vodika, halogena, cijano, C1-6-alk(en/in)ila, hidroksi, C1-6-alk(en/in)iloksi i halo-C1-6-alk(en/in)ila.
6. Spoj prema bilo kojem od zahtjeva 1-5, naznačen time, što je spomenuti spoj izabran između spojeva sa slijedeće liste:
[image]
[image]
u vidu njegove slobodne baze ili soli.
7. Farmaceutska kompozicija, naznačena time što sadrži spoj prema bilo kojem od zahtjeva 1-6 i najmanje jedan farmaceutski prihvatljivi nosač ili razrjeđivač.
8. Spoj prema bilo kojem od zahtjeva 1-6, naznačen time, što se koristi za primjenu u liječenju bolesti ili poremećaja, pri čemu je koristan kombinirani inhibitor resorpcije serotonina, noradrenalina i dopamina.
9. Spoj prema zahtjevu 8, naznačen time, što je spomenuti poremećaj ili bolest afektivni poremećaj.
10. Spoj prema zahtjevu 9, naznačen time, što je afektivni poremećaj depresivni poremećaj.
11. Spoj prema zahtjevu 10, naznačen time, što je spomenuti depresivni poremećaj veliki depresivni poremećaj, postnatalna depresija, distimija ili depresija koja je povezana sa bipolarnim poremećajem, Alchajmerovom bolesti, psihozom ili Parkinsonovom bolesti.
12. Spoj prema zahtjevu 9, naznačen time, što je afektivni poremećaj anksiozni poremećaj.
13. Spoj prema zahtjevu 12, naznačen time, što spomenuti anksiozni poremećaj predstavljaju generalizirani anksiozni poremećaj, socijalni anksiozni poremećaj, post-traumatski stresni poremećaj, opsesivno-kompulzivni poremećaj, panični poremećaj, napadi panike, specifične fobije, socijalna fobija i agorafobija.
14. Spoj prema zahtjevu 8, naznačen time, što je spomenuti poremećaj ili bolest bolni poremećaj.
15. Spoj prema zahtjevu 14, naznačen time, što je spomenuti bolni poremećaj sindrom fibromijalgije, difuzni bol, bol u leđima, bol u ramenu, glavobolja, kao i bol tokom budnog stanja ili tokom dnevnih aktivnosti.
16. Spoj prema zahtjevu 8, naznačen time, što je spomenuti poremećaj ili bolest poremećaj hiperaktivnosti i deficita pažnje ili urinarna stres inkontinencija.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53259303P | 2003-12-23 | 2003-12-23 | |
DKPA200301923 | 2003-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110400T1 true HRP20110400T1 (hr) | 2011-06-30 |
Family
ID=34712442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20080274T HRP20080274T3 (hr) | 2003-12-23 | 2008-06-19 | 2-(1h-indolilsulfanil)-benzil amin derivati kao ssri |
HR20110400T HRP20110400T1 (hr) | 2003-12-23 | 2011-05-27 | Derivati 2-(1h-indolilsulfanil)-benzil amina kao ssri |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20080274T HRP20080274T3 (hr) | 2003-12-23 | 2008-06-19 | 2-(1h-indolilsulfanil)-benzil amin derivati kao ssri |
Country Status (18)
Country | Link |
---|---|
US (4) | US7563908B2 (hr) |
EP (1) | EP1701940B1 (hr) |
JP (3) | JP4090491B2 (hr) |
AT (1) | ATE396970T1 (hr) |
AU (1) | AU2004303461B2 (hr) |
BR (1) | BRPI0417858B1 (hr) |
CY (2) | CY1108230T1 (hr) |
DE (1) | DE602004014190D1 (hr) |
DK (1) | DK1701940T3 (hr) |
ES (1) | ES2303960T3 (hr) |
HR (2) | HRP20080274T3 (hr) |
IL (1) | IL176111A (hr) |
MX (1) | MXPA06007172A (hr) |
PL (1) | PL1701940T3 (hr) |
PT (1) | PT1701940E (hr) |
RS (1) | RS50589B (hr) |
SI (1) | SI1701940T1 (hr) |
WO (1) | WO2005061455A1 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1701940T3 (pl) * | 2003-12-23 | 2008-11-28 | H Lundbeck As | Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI |
AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
AR054393A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
US20090054510A1 (en) * | 2006-03-22 | 2009-02-26 | H. Lundbeck A/S | Method for identifying compounds for the treatment of depression |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
AU2007302449A1 (en) * | 2006-09-28 | 2008-04-03 | H. Lundbeck A/S | [2-(6-fluoro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
CN101563320B (zh) * | 2006-09-28 | 2012-05-30 | H.隆德贝克有限公司 | 用于治疗情感障碍的[2-(6-氟-1h-吲哚-3-基硫烷基)苄基]甲胺 |
CN101868233A (zh) * | 2007-09-24 | 2010-10-20 | H.隆德贝克有限公司 | 与血清素双重作用化合物有关的组合疗法 |
TW200938189A (en) * | 2008-03-13 | 2009-09-16 | Lundbeck & Co As H | [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
WO2010006945A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Substituted indolyl and indazolyl derivatives and uses thereof |
CN103201262B (zh) * | 2010-08-20 | 2016-06-01 | 艾米拉医药股份有限公司 | 自分泌运动因子抑制剂及其用途 |
US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
JP2016530209A (ja) | 2013-09-17 | 2016-09-29 | ファーマケア,インク. | ビニルオートタキシン阻害剤化合物 |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
JP2016531874A (ja) | 2013-09-26 | 2016-10-13 | ファーマケア,インク. | オートタキシン阻害剤化合物 |
PT3071561T (pt) | 2013-11-22 | 2021-06-25 | Sabre Therapeutics Llc | Compostos inibidores de autotaxina |
EP4026549A1 (en) | 2015-05-27 | 2022-07-13 | Sabre Therapeutics LLC | Autotaxin inhibitors and uses thereof |
US11339144B2 (en) | 2017-04-10 | 2022-05-24 | Navitor Pharmaceuticals, Inc. | Heteroaryl Rheb inhibitors and uses thereof |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003023A (en) * | 1930-10-16 | 1935-05-28 | Westinghouse Electric & Mfg Co | Mercury vapor or noble gas rectifier with arc control |
US3803143A (en) * | 1969-09-08 | 1974-04-09 | Eisai Co Ltd | 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines |
US4018830A (en) * | 1969-09-22 | 1977-04-19 | Merck & Co., Inc. | Phenylthioaralkylamines |
US4055665A (en) * | 1974-11-25 | 1977-10-25 | Merck & Co., Inc. | Treating arrythmia with phenylthioaralkylamines |
US4056632A (en) * | 1975-07-21 | 1977-11-01 | Burroughs Wellcome Co. | 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use |
US4241071A (en) * | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
DE3640475A1 (de) | 1986-11-27 | 1988-06-09 | Hoechst Sa Lab | Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung |
EP0396827A1 (en) | 1989-05-09 | 1990-11-14 | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu | 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof |
GB8912971D0 (en) | 1989-06-06 | 1989-07-26 | Wellcome Found | Halogen substituted diphenylsulfides |
US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
ES2143992T3 (es) | 1991-11-25 | 2000-06-01 | Pfizer | Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas. |
GB9126311D0 (en) | 1991-12-11 | 1992-02-12 | Wellcome Found | Substituted diphenylsulfides |
GB9226532D0 (en) | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
EP0755923B1 (en) | 1995-01-23 | 2005-05-04 | Daiichi Suntory Pharma Co., Ltd. | Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor |
EP0907654B1 (en) | 1995-11-06 | 2000-08-02 | Dsm N.V. | De-esterification process |
CZ293595A3 (cs) | 1995-11-09 | 1999-12-15 | Farmak A. S. | Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích |
US5912256A (en) * | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
KR20000035880A (ko) * | 1996-08-27 | 2000-06-26 | 이곤 이 버그 | 도파민 d2 효능제 및 5ht1a 리간드로서의 4-아미노에톡시 인돌 |
US5906078A (en) * | 1996-10-09 | 1999-05-25 | Gallagher-Kaiser Corporation | Retaining strip for sheet covered enclosures |
GB9725953D0 (en) | 1997-12-08 | 1998-02-04 | Pfizer Ltd | Compounds useful in therapy |
DE19756036A1 (de) * | 1997-12-17 | 1999-06-24 | Merck Patent Gmbh | Amid- und Harnstoffderivate |
US6333146B1 (en) * | 1999-03-10 | 2001-12-25 | Fuji Photo Film Co., Ltd. | Methine compound and silver halide photographic material containing the same |
CN1721401A (zh) | 1999-04-02 | 2006-01-18 | 伊科斯公司 | 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途 |
AU780725B2 (en) | 1999-04-30 | 2005-04-14 | Trustees Of The University Of Pennsylvania, The | Spect imaging agents for serotonin transporters |
AU6621600A (en) | 1999-08-04 | 2001-03-05 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
PL355289A1 (en) * | 1999-10-13 | 2004-04-05 | Pfizer Products Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
US6410736B1 (en) * | 1999-11-29 | 2002-06-25 | Pfizer Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
TR200201683T2 (tr) | 1999-12-30 | 2002-12-23 | H. Lundbeck A/S | İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları |
CN1244577C (zh) | 1999-12-30 | 2006-03-08 | H.隆德贝克有限公司 | 4-苯基-1-哌嗪基、-哌啶基和-四氢吡啶基衍生物 |
ATE261958T1 (de) | 1999-12-30 | 2004-04-15 | Lundbeck & Co As H | Phenylpiperazinyl-derivate |
EP1267868B1 (en) * | 2000-02-29 | 2007-07-18 | MediQuest Therapeutics, Inc. | Inhibitors of melanocyte tyrosinase as topical skin lighteners |
AU2001258771A1 (en) * | 2000-05-19 | 2001-11-26 | Takeda Chemical Industries Ltd. | -secretase inhibitors |
US6455738B1 (en) * | 2000-07-13 | 2002-09-24 | Rhodia Chimie | Process for the sulfonation of an aromatic compound |
WO2002006234A1 (fr) * | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Derives de sulfonate, procede de production et utilisation de ces derives |
WO2002015910A1 (en) * | 2000-08-18 | 2002-02-28 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
KR20030059107A (ko) * | 2000-09-01 | 2003-07-07 | 에프엠씨 코포레이션 | 살충제로서의 이치환된 벤젠 |
AU2001288623A1 (en) * | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
EP1193268A1 (en) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
US6852816B2 (en) * | 2000-10-06 | 2005-02-08 | Biocompatibles Uk Limited | Zwitterionic polymers |
EP1578341A2 (en) * | 2000-10-11 | 2005-09-28 | Tularik Inc. | Modulation of ccr4 function |
BR0115296A (pt) | 2000-11-14 | 2003-09-02 | Merck Patent Ges Mit Beschonkt | Uso de inibidores de recaptação de sorotonina e agonistas de 5ht1a combinados |
US6436938B1 (en) * | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
JP4187642B2 (ja) | 2001-06-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を有する新規インドール誘導体 |
EP1403255A4 (en) * | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
US7064139B2 (en) * | 2001-10-29 | 2006-06-20 | Uniroyal Chemical Company, Inc. | Method for treating retroviral infections |
HUP0401924A3 (en) * | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
MXPA04006119A (es) | 2001-12-21 | 2004-11-01 | Lundbeck & Co As H | Derivados aminoindano como inhibidores de la absorcion de la serotonina y de la norepinefrina. |
ATE371680T1 (de) * | 2002-01-16 | 2007-09-15 | Biocompatibles Uk Ltd | Polymerkonjugate |
US20050261298A1 (en) * | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
DE60318267T2 (de) * | 2002-03-01 | 2008-12-11 | Fujifilm Corp. | Farbphotographisches lichtempfindliches Silberhalogenidmaterial |
US7829044B2 (en) * | 2002-03-04 | 2010-11-09 | Japan Science And Technology Agency | Phosphonamides, process for producing the same, and use thereof |
CA2480518C (en) * | 2002-03-29 | 2016-07-19 | Massachusetts Institute Of Technology | Light emitting device including semiconductor nanocrystals |
DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
CN1662496A (zh) * | 2002-06-19 | 2005-08-31 | 先灵公司 | 大麻素受体激动剂 |
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
MXPA05002836A (es) * | 2002-09-17 | 2005-05-27 | Hoffmann La Roche | Indoles 2,4-sustituidos y su uso como moduladores 5-ht6. |
JP4327091B2 (ja) * | 2002-09-17 | 2009-09-09 | エフ.ホフマン−ラ ロシュ アーゲー | 2,7−置換インドール及び5−ht6モジュレーターとしてのその使用 |
EP1402888A1 (en) * | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
US20040266732A1 (en) * | 2002-09-20 | 2004-12-30 | Jorge Galvez | Therapeutic agents, methods, and treatments |
US20060189519A1 (en) * | 2002-09-26 | 2006-08-24 | Karl Volz | Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf) |
US20040137389A1 (en) * | 2002-12-19 | 2004-07-15 | Kouta Fukui | Heat-developable light-sensitive material |
NZ541234A (en) * | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
US7189501B2 (en) * | 2002-12-27 | 2007-03-13 | Fuji Photo Film Co., Ltd. | Silver halide color photographic photosensitive material |
DE10300098A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Ag | Kupfer-Carben-Komplexe und ihre Verwendung |
EP2267049A1 (en) * | 2003-02-05 | 2010-12-29 | Biocompatibles UK Limited | Block copolymers |
AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
EP2258365B1 (en) * | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
EP1671962A1 (en) * | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
US7229751B2 (en) * | 2003-11-20 | 2007-06-12 | Konica Minolta Medical & Graphic, Inc. | Silver salt photothermographic dry imaging material and image forming method using the same |
CA2550091A1 (en) * | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
PL1701940T3 (pl) * | 2003-12-23 | 2008-11-28 | H Lundbeck As | Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI |
SE528250C2 (sv) | 2004-02-27 | 2006-10-03 | Calignum Technologies Ab | Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen |
JP4569142B2 (ja) * | 2004-03-22 | 2010-10-27 | コニカミノルタホールディングス株式会社 | 表示素子 |
JP4448730B2 (ja) * | 2004-04-20 | 2010-04-14 | 富士フイルム株式会社 | 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法 |
WO2006006172A2 (en) | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
EP1793816B1 (en) | 2004-08-19 | 2012-01-04 | Tel Aviv University Future Technology Development L.P. | Compositions for treating amyloid associated diseases |
EP1793272A4 (en) | 2004-08-24 | 2008-01-23 | Fujifilm Corp | PHOTOGRAPHIC PHOTOSENSITIVE COLOR MATERIAL BASED ON SILVER HALIDE AND METHOD OF FORMING IMAGES |
CN101068777A (zh) | 2004-10-08 | 2007-11-07 | 万有制药株式会社 | 硫醚化合物的制备方法 |
WO2006063606A1 (en) | 2004-12-16 | 2006-06-22 | Pirelli & C. S.P.A. | Process for manufacturing a thermoplastic elastomeric material |
-
2004
- 2004-12-21 PL PL04803045T patent/PL1701940T3/pl unknown
- 2004-12-21 MX MXPA06007172A patent/MXPA06007172A/es active IP Right Grant
- 2004-12-21 ES ES04803045T patent/ES2303960T3/es active Active
- 2004-12-21 DK DK04803045T patent/DK1701940T3/da active
- 2004-12-21 WO PCT/DK2004/000894 patent/WO2005061455A1/en active Application Filing
- 2004-12-21 JP JP2006545921A patent/JP4090491B2/ja not_active Expired - Fee Related
- 2004-12-21 AU AU2004303461A patent/AU2004303461B2/en not_active Ceased
- 2004-12-21 AT AT04803045T patent/ATE396970T1/de active
- 2004-12-21 SI SI200430784T patent/SI1701940T1/sl unknown
- 2004-12-21 PT PT04803045T patent/PT1701940E/pt unknown
- 2004-12-21 RS RSP-2008/0315A patent/RS50589B/sr unknown
- 2004-12-21 BR BRPI0417858-0A patent/BRPI0417858B1/pt not_active IP Right Cessation
- 2004-12-21 EP EP04803045A patent/EP1701940B1/en active Active
- 2004-12-21 DE DE602004014190T patent/DE602004014190D1/de active Active
-
2005
- 2005-12-21 US US11/314,702 patent/US7563908B2/en not_active Expired - Fee Related
-
2006
- 2006-06-04 IL IL176111A patent/IL176111A/en active IP Right Grant
-
2007
- 2007-06-05 JP JP2007148813A patent/JP4091648B2/ja active Active
- 2007-12-07 JP JP2007316676A patent/JP2008110984A/ja not_active Ceased
-
2008
- 2008-03-07 US US12/044,170 patent/US7652150B2/en not_active Expired - Fee Related
- 2008-03-17 US US12/049,403 patent/US7737171B2/en not_active Expired - Fee Related
- 2008-03-17 US US12/049,401 patent/US7737170B2/en not_active Expired - Fee Related
- 2008-06-19 HR HR20080274T patent/HRP20080274T3/hr unknown
- 2008-07-30 CY CY20081100801T patent/CY1108230T1/el unknown
-
2011
- 2011-05-20 CY CY20111100495T patent/CY1111733T1/el unknown
- 2011-05-27 HR HR20110400T patent/HRP20110400T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110400T1 (hr) | Derivati 2-(1h-indolilsulfanil)-benzil amina kao ssri | |
YU21602A (sh) | Derivati biaril etra korisni kao inhibitori ponovnog podizanja monoamina | |
NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
EA200400498A1 (ru) | Производные фенилпиперазина как ингибиторы обратного захвата серотонина | |
NO20062139L (no) | Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister | |
EA200100748A1 (ru) | Ингибиторы обратного захвата моноаминов для лечения расстройств цнс | |
MEP52408A (en) | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | |
MX2009013218A (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus. | |
TW200613272A (en) | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | |
NZ705710A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
MX2007012936A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
MY148988A (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
TW200531694A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
TW201110962A (en) | Carbocyclic GlyT1 receptor antagonists | |
CA2570805A1 (en) | 2-(1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence | |
DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
MY129575A (en) | Methods, kits and compositions for using pyrrole derivatives againts anxiety | |
CA2551168A1 (en) | 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri |